Commercialization, • 9/19/25 What Matters to Payers: Conversations You Should Start During Phase 2 Previous Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories You Might Also Like Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials Leveraging Patient Advocacy To Scale Rare Disease Trials Closing Panel: Beyond “One Disease At a Time”: Platform Approaches to Accelerate Gene Therapy Trials Optimizing Rare Disease Clinical Trials with Real World Data Using NLP & AI Patient Recruitment and Engagement in in Global, Multisite Rare Disease Trials
Commercialization, • 9/19/25 What Matters to Payers: Conversations You Should Start During Phase 2 Previous Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories You Might Also Like Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials Leveraging Patient Advocacy To Scale Rare Disease Trials Closing Panel: Beyond “One Disease At a Time”: Platform Approaches to Accelerate Gene Therapy Trials Optimizing Rare Disease Clinical Trials with Real World Data Using NLP & AI Patient Recruitment and Engagement in in Global, Multisite Rare Disease Trials
